Transdermal PTEN mRNA Delivery via HA-LNPs in Melanoma Models

Study Background and Research Question

Melanoma remains among the most aggressive and treatment-resistant forms of skin cancer, characterized by frequent immune evasion and high metastatic potential. While immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 antibodies have advanced clinical care, overall response rates are limited by mechanisms of resistance, including the loss or mutation of the phosphatase and tensin homolog (PTEN) tumor suppressor gene. PTEN regulates cell growth, apoptosis, and immune responses mainly by antagonizing the PI3K/Akt signaling pathway. Its deficiency not only drives unchecked proliferation but also diminishes T cell-mediated antitumor immunity, thereby promoting ICI resistance and tumor progression. The central question addressed by Kim et al. in their 2026 study is whether non-viral, transdermal mRNA delivery systems can restore PTEN expression locally in melanoma, thereby overcoming immune escape and enhancing the efficacy of immunotherapy.

Key Innovation from the Reference Study

The innovation reported by Kim and colleagues centers on the design and application of hyaluronated lipid nanoparticles (HA-LNPs) as a vehicle for localized, transdermal delivery of PTEN mRNA. Unlike traditional PEGylated lipid nanoparticles—which can provoke immunogenic reactions and require additional surface modification—these HA-LNPs employ a hyaluronate-dimyristoyl glycerol (HA-DMG) conjugate that integrates stably into the LNP bilayer during self-assembly. This approach offers dual benefits: eliminating the need for polyethylene glycol (PEG) while endowing the nanoparticles with HA moieties for improved skin penetration and CD44-mediated tumor targeting. The platform is designed to encapsulate large mRNA payloads efficiently, facilitating non-invasive delivery directly to tumor and skin-resident immune cells.

Methods and Experimental Design Insights

The experimental workflow established by Kim et al. involved several key steps:

• Synthesis and characterization of HA-DMG conjugates, ensuring amphiphilicity and compatibility with lipid bilayer assembly.
• Formulation of HA-LNPs via microfluidic mixing, enabling reproducible particle size distribution and efficient encapsulation of in vitro transcribed human PTEN mRNA.
• In vitro validation using melanoma cell lines to assess nanoparticle uptake, mRNA transfection and expression, and cytotoxic effects.
• In vivo evaluation in mouse melanoma models, focusing on skin penetration, tumor localization, PTEN restoration, tumor suppression, and immune activation following topical application.

Crucially, the study compared the performance of HA-LNPs with conventional PEG-LNPs, highlighting differences in colloidal stability, biocompatibility, and targeting specificity.

Core Findings and Why They Matter

Kim et al. demonstrated that HA-LNPs encapsulating PTEN mRNA achieve several critical outcomes (reference):

• Efficient mRNA encapsulation and transfection: The HA-LNPs stably encapsulated human PTEN mRNA and mediated robust cytosolic delivery in CD44-expressing melanoma cells.
• Restoration of PTEN function: Transfected cells displayed re-expression of functional PTEN, leading to inhibition of PI3K/Akt signaling, reduced cell viability, and induction of immunogenic cell death (ICD).
• Enhanced tumor and skin penetration: Topical application of HA-LNPs resulted in deep skin and tumor tissue penetration, attributed to HA-mediated interactions with CD44 and extracellular matrix components.
• Antitumor efficacy and immune activation in vivo: In melanoma-bearing mice, transdermal HA-LNP delivery of PTEN mRNA significantly suppressed tumor growth and promoted immune cell infiltration, with minimal off-target toxicity.
• PEG-free formulation advantages: Compared to PEG-LNPs, HA-LNPs displayed improved biocompatibility, reduced risk of hypersensitivity, and superior targeting of CD44+ tumor and immune cells.

This evidence positions HA-LNP-mediated delivery of tumor suppressor gene mRNA as a promising alternative to viral and DNA-based approaches, leveraging the transient, non-integrating nature of mRNA therapeutics and the targeting properties of HA.

Comparison with Existing Internal Articles

The reference study aligns closely with themes discussed in several recent thought-leadership and protocol-oriented articles:

• The internal resource "Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Therapy" provides an overview of the same HA-LNP platform, highlighting its potential to locally restore PTEN expression and potentiate immunotherapy. Kim et al.'s data further strengthen the rationale for this delivery strategy in preclinical models.
• "Restoring PTEN: Strategic mRNA Approaches for Translational Oncology" synthesizes mechanistic and workflow insights, emphasizing the translational strengths of mRNA formats—such as those with Cap 1 structures and poly(A) tails—for gene therapy research. The reference paper's demonstration of functional PTEN protein restoration and immune engagement validates these mechanistic predictions.
• "Translating PTEN mRNA Insights: Mechanisms, Models, and Strategy" expands on nanoparticle-mediated mRNA delivery to the tumor microenvironment, a strategy exemplified by the HA-LNP approach detailed in Kim et al.'s work.

Together, these resources provide a robust contextual framework for understanding how HA-LNPs and advanced mRNA designs can enhance tumor suppressor gene mRNA research and translational cancer immunotherapy.

Protocol Parameters

• HA-LNP formulation: Assemble nanoparticles via microfluidic mixing of HA-DMG conjugate, helper lipids, and mRNA at optimized ratios to achieve particle sizes of ~80–120 nm and high encapsulation efficiency.
• mRNA payload specification: Employ in vitro transcribed human PTEN mRNA with Cap 1 structure and poly(A) tail to maximize translation and minimize innate immune activation, as supported by the EZ Cap™ Human PTEN mRNA product specifications.
• Topical application: Apply HA-LNPs loaded with PTEN mRNA to shaved skin overlying the tumor daily or as specified in the experimental design; monitor skin penetration and tumor localization by fluorescence or molecular assays.
• Functional readouts: Assess PTEN protein restoration, PI3K/Akt pathway inhibition, tumor growth, immune cell infiltration, and evidence of immunogenic cell death in treated tissues.

Limitations and Transferability

Despite promising preclinical results, several limitations should be considered:

• Species differences: Mouse skin and tumor microenvironments differ from human tissues in structure, immune composition, and CD44 expression, potentially influencing translatability.
• Long-term safety: While acute toxicity and immunogenicity were minimal in vivo, chronic exposure and repeated dosing require further evaluation.
• Manufacturing scalability: The synthesis of HA-DMG and large-scale assembly of HA-LNPs must be validated for clinical-grade production and reproducibility.
• Therapeutic durability: mRNA-based protein expression is inherently transient, necessitating optimization of dosing regimens for sustained therapeutic effect.

Transferability to other tumor types or mRNA targets will depend on the expression of CD44 in the target tissue and the compatibility of the HA-LNP platform with alternative mRNA cargos.

Research Support Resources

For researchers seeking to replicate or extend these workflows, high-quality, in vitro transcribed mRNA reagents are essential. EZ Cap™ Human PTEN mRNA (SKU R1025) is a rigorously validated mRNA product encoding the human PTEN gene, featuring a Cap 1 structure and poly(A) tail for enhanced stability and translation. This reagent can be complexed with lipid nanoparticles or other delivery systems to investigate PTEN restoration, PI3K/Akt signaling, and immunogenic effects in both in vitro and in vivo models. Adoption of such workflow-ready, quality-controlled mRNA supports reproducibility and efficiency in tumor suppressor gene mRNA and cancer research applications.